0001567619-23-001153.txt : 20230123 0001567619-23-001153.hdr.sgml : 20230123 20230123195003 ACCESSION NUMBER: 0001567619-23-001153 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230119 FILED AS OF DATE: 20230123 DATE AS OF CHANGE: 20230123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bejar Rafael CENTRAL INDEX KEY: 0001797382 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32001 FILM NUMBER: 23545597 MAIL ADDRESS: STREET 1: C/O APTOSE BIOSCIENCES INC. STREET 2: 251 CONSUMERS ROAD, SUITE 1105 CITY: TORONTO STATE: A6 ZIP: M2J 4R3 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aptose Biosciences Inc. CENTRAL INDEX KEY: 0000882361 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 251 CONSUMERS ROAD STREET 2: SUITE 1105 CITY: TORONTO STATE: A6 ZIP: M2J 4R3 BUSINESS PHONE: 647-479-9828 MAIL ADDRESS: STREET 1: 251 CONSUMERS ROAD STREET 2: SUITE 1105 CITY: TORONTO STATE: A6 ZIP: M2J 4R3 FORMER COMPANY: FORMER CONFORMED NAME: Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.) DATE OF NAME CHANGE: 20140905 FORMER COMPANY: FORMER CONFORMED NAME: LORUS THERAPEUTICS INC DATE OF NAME CHANGE: 19990308 FORMER COMPANY: FORMER CONFORMED NAME: IMUTEC PHARMA INC DATE OF NAME CHANGE: 19970113 4 1 doc1.xml FORM 4 X0306 4 2023-01-19 0 0000882361 Aptose Biosciences Inc. APTO 0001797382 Bejar Rafael C/O APTOSE BIOSCIENCES INC. 251 CONSUMERS ROAD, SUITE 1105 TORONTO A6 M2J 4R3 ONTARIO, CANADA 0 1 0 0 Sr. VP, Chief Medical Officer Common Shares 2023-01-19 4 A 0 100000 0 A 110000 D Employee Stock Option 0.66 2023-01-19 4 A 0 200000 0 A 2033-01-19 Common Shares 200000 200000 D Fifty percent (50%) of the options vest on January 19, 2024; the remaining fifty percent (50%) vest as follows: one-third (1/3) on January 19, 2025; one-third (1/3) on January 19, 2026; and one-third on January 19, 2027. /s/ Fletcher Payne as attorney-in-fact for Rafael Bejar 2023-01-23